Harnessing Nanogold in Therapeutic Cancer Vaccines
Abstract Cancer immunotherapy offers potential to harness one’s own immune system to eliminate existing cancer cells. Within this therapeutic umbrella, therapeutic cancer vaccines (TCVs) have been designed to train lymphocytes to recognize cancer cells as foreign invaders and eliminate them from the body. To enact this training, scientists have employed nanoscale gold constructs (nanogold) in varying ways throughout the cyclical process of antigen uptake, dendritic cell maturation, antigen presentation, T cell migration, and cancer cell elimination. In this review, we highlight the use of nanogold in TCVs, emphasizing the distinct properties that have been harnessed to improve diverse aspects of the TCV cycle. Ultimately, we discuss the challenges of utilizing nanogold in TCVs and provide our perspective on the direction of the field in upcoming years.
Authors
- Joshua Seaberg (ORCID: https://orcid.org/0000-0003-1158-055X)
- Priyabrata Mukherjee (ORCID: https://orcid.org/0000-0002-0557-0833)
- Resham Bhattacharya (ORCID: https://orcid.org/0000-0003-2523-0569)
Publication Details
- Journal
- ACS Nano Medicine
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1021/acsnanomed.6c00228
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00